Current Diabetes Reports

, 14:518

Interleukin-7 and Type 1 Diabetes

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pathogenesis of Type 1 Diabetes


Antigen-experienced T-cells directly target and destroy insulin-producing beta cells in patients with Type 1 diabetes. Consequently, T-cells are also major targets of immunomodulatory strategies that aim to prevent or delay the immune mediated loss of islet beta-cell function. These strategies have had modest success, prompting efforts into better defining the mechanisms that drive the differentiation of quiescent autoreactive clones into pathogenic effector and memory T-cells. Recent and novel findings now indicate that in addition to the classic mechanisms of antigenic recognition, autoreactive T-cell differentiation and expansion can be boosted by the homeostatic cytokine interleukin-7. In this article, we discuss recent evidence of the role of IL-7 mediated T-cell proliferation in the pathogenesis of Type 1 diabetes and the rationale for including immunomodulatory molecules targeting the IL-7/IL-7R axis in immunotherapeutic strategies to control beta-cell autoimmunity.


Type 1 diabetes Interleukin-7 IL-7 IL-7 receptor Soluble IL-7Rα sCD127 Homeostatic proliferation T-cells 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia. 2003;46:305–21.PubMedGoogle Scholar
  2. 2.
    Di Lorenzo TP, Peakman M, Roep BO. Translational mini-review series on Type 1 diabetes: systematic analysis of T-cell epitopes in autoimmune diabetes. Clin Exp Immunol. 2007;148:1–16.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Achenbach P, Warncke K, Reiter J, et al. Stratification of Type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004;53:384–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Danke NA, Yang J, Greenbaum C, et al. Comparative study of GAD65-specific CD4+ T-cells in healthy and Type 1 diabetic subjects. J Autoimmun. 2005;25:303–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Viglietta V, Kent SC, Orban T, et al. GAD65-reactive T-cells are activated in patients with autoimmune Type 1a diabetes. J Clin Invest. 2002;109:895–903.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Monti P, Scirpoli M, Rigamonti A, et al. Evidence for in vivo primed and expanded autoreactive T-cells as a specific feature of patients with Type 1 diabetes. J Immunol. 2007;179:5785–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Von Herrath M, Peakman M, Roep B. Progress in immune-based therapies for Type 1 diabetes. Clin Exp Immunol. 2013;172:186–202.PubMedCentralCrossRefGoogle Scholar
  8. 8.
    Schneider A, Rieck M, Sanda S, et al. The effector T-cells of diabetic subjects are resistant to regulation via CD4 + FOXP3+ regulatory T-cells. J Immunol. 2008;181:7350–5.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset Type 1 diabetes: a randomised double-blind trial. Lancet. 2011;378:319–27.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of Type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378:487–97.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Orban T, Bundy B, Becker D, et al. Co-stimulation modulation with abatacept in patients with recent-onset Type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412–9.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Couri CEB, Oliveira M, Stracieri A, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus. JAMA. 2009;301:1573–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Monti P, Heninger AK, Bonifacio E. Homeostasis of autoreactive T-cells in Type 1 diabetes mellitus. Curr Diabetes Rep. 2009;9:113–8.CrossRefGoogle Scholar
  14. 14.
    Schluns KS, Kieper WC, Jameson SC, et al. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T-cells in vivo. Nat Immunol. 2000;1:426–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Kondrack RM, Harbetrson J, Tan JT, et al. Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med. 2003;198:1797–806.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Palmer MJ, Mahajan VS, Trajman L, et al. Perspectives on the quantitative immunobiology of the IL-7 signaling network. Cell Mol Immunol. 2009;5:79–89.CrossRefGoogle Scholar
  17. 17.
    Dummer W, Niethammer AG, Baccala R, et al. T-cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002;110:157–9.CrossRefGoogle Scholar
  18. 18.
    Dean RM, Fry T, Mackall C, et al. Association of serum interleukin-7 levels with the development of acute graft-vs-host disease. J Clin Oncol. 2008;26:5735–41.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001;7:73–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Monti P, Scirpoli M, Maffi P, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T-cells. J Clin Invest. 2008;118:73–9.Google Scholar
  21. 21.•
    Heninger AK, Theil A, Wilhelm C, et al. IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T-cells and allows expansion of alloreactive and autoreactive T-cells. J Immunol. 2012;189:5649–58. This paper shows that an IL-7-rich environment encourages naïve Treg proliferation but abrogation of Treg suppressive function. The net effect can lead to the expansion of autoreactive T-cells specific for beta-cell antigens.PubMedCrossRefGoogle Scholar
  22. 22.
    Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T-cells in lymphopenic hosts. Immunity. 1999;11:183–90.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Gattinoni L, Zhong X, Palmer D, et al. Wnt signaling arrests effector T-cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15:808–13.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Gattinoni L, Lugli E, Ji Y, et al. A human memory T-cell subset with stem cell-like properties. Nat Med. 2011;17:1290–7.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Muranski P, Borman ZA, Kerkar SP, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 2011;35:972–85.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.••
    Cieri N, Camisa B, Cocchiarella F, et al. IL-7 and IL-15 instruct the generation of human memory stem T-cells from naive precursors. Blood. 2013;121:573–84. This work shows that human memory stem T-cells can be generated from naive T-cells by culture with antigen plus IL-7 and IL-15.PubMedCrossRefGoogle Scholar
  27. 27.
    King C, Ilic A, Koelsch K, et al. Homeostatic expansion of T-cells during immune insufficiency generates autoimmunity. Cell. 2004;117:265–77.PubMedCrossRefGoogle Scholar
  28. 28.
    Calzascia T, Pellegrini M, Lin A, et al. CD4 T-cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. PNAS. 2008;105:2999–3004.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.••
    Penaranda C, Kuswanto W, Hofmann J, et al. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T-cells. PNAS. 2012;109:12668–73. This and the following reference show that IL-7R blockade prevents beta-cell destruction and can reverse established diabetes in the NOD mouse model by increasing PD-1 expression and inhibiting effector and memory T-cells.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.••
    Lee L, Logronio G, Huan G, et al. Anti–IL-7 receptor-α reverses established Type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. PNAS. 2012;109:12674–9. This is the companion paper of Penaranda et al.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol. 2007;7:144–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Hartgring SAY, van Roon JAG, van Wijk MW, et al. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthr Rheum. 2009;60:2595–605.CrossRefGoogle Scholar
  33. 33.
    Laakso SM, Kekalainen E, Rossi LH, et al. IL-7 dysregulation and loss of CD8+ T-cell homeostasis in the monogenic human disease autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Immunol. 2011;187:2023–30.PubMedCrossRefGoogle Scholar
  34. 34.
    Lundmark F, Duvefelt K, Iacobaeus E, et al. Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis. Nat Gen. 2007;39:1108–13.CrossRefGoogle Scholar
  35. 35.
    Parikka V, Näntö-Salonen K, Saarinen M, et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of Type 1 diabetes in children at genetic risk. Diabetologia. 2012;55:1926–36.PubMedCrossRefGoogle Scholar
  36. 36.
    Ziegler AG, Bonifacio E. Age-related islet autoantibody incidence in offspring of patients with Type 1 diabetes. Diabetologia. 2012;55:1937–43.PubMedCrossRefGoogle Scholar
  37. 37.•
    Heninger AK, Monti P, Wilhelm C, et al. Activation of islet autoreactive naive T-cells in infants is influenced by homeostatic mechanisms and antigen-presenting capacity. Diabetes. 2013;62:2059–66. IL-7 concentrations at birth and early infancy are shown to be increased. Moreover, the responsiveness of T-cells to IL-7 was markedly increased in the first year of life. The manuscript suggested that the increased IL-7 driven expansion may be a mechanism contributing to a heightened risk of beta-cell autoimmunity at around 1 year of age.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Bosi E, Braghi S, Maffi P, et al. Autoantibody response to islet transplantation in Type 1 diabetes. Diabetes. 2001;50:2464–71.PubMedCrossRefGoogle Scholar
  39. 39.
    Vendrame F, Pileggi A, Laughlin E, et al. Recurrence of Type 1 diabetes after simultaneous pancreas/kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic auto reactive CD4+ T-cells. Diabetes. 2010;59:947–57.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Hilbrands R, Huurman V, Gillard P, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in Type 1 diabetic patients. Diabetes. 2009;58:2267–76.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Braghi S, Bonifacio E, Secchi A, et al. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with Type 1 diabetes. Diabetes. 2000;49:218–24.PubMedCrossRefGoogle Scholar
  42. 42.
    Goodwin RG, Friend D, Ziegler S, et al. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell. 1990;60:941–51.PubMedCrossRefGoogle Scholar
  43. 43.
    Teutsch SM, Booth DR, Bennetts BH, et al. Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-alpha gene and their associations with multiple sclerosis. Eur J Hum Genet. 2003;11:509–14.PubMedCrossRefGoogle Scholar
  44. 44.
    McKay F, Swain L, Schibeci S, et al. Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. Gen Immunol. 2008;9:1–6.CrossRefGoogle Scholar
  45. 45.
    Selinsky CL, Howell MD. Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo. Cell Immunol. 2000;200:81–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Rose-John S, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors : role in inflammation and cancer. J Leuk Biol. 2006;80:227–36.CrossRefGoogle Scholar
  47. 47.
    Stoklasek TA, Schluns KS, Lefranc L. Combined IL-15/IL-15Ra immunotherapy maximizes IL-15 activity In Vivo 1. J Immunol. 2012;177:6072–80.CrossRefGoogle Scholar
  48. 48.••
    Monti P, Brigatti C, Krasmann M, et al. Concentration and activity of the soluble form of the Interleukin-7 Receptor alpha in type I diabetes identifies an interplay between hyperglycemia and immune function. Diabetes. 2013;62:2500–8. Here it is shown that the soluble form of the IL-7Ra (sCD127) down-regulates IL-7 activity, but that glycation of sCD127 abolishes this effect. Patients with Type 1 diabetes have increased concentrations of sCD127, but a substantial portion of this appears glycated demonstrating how hyperglycemia may interfere with natural mechanisms of immune regulation.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Crawley AM, Faucher S, Angel JB. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol. 2010;184:4679–87.PubMedCrossRefGoogle Scholar
  50. 50.
    Lundström W, Highfill S, Walsh S, et al. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. PNAS. 2013;110:1761–70.CrossRefGoogle Scholar
  51. 51.
    Esposito K, Nappo F, Marfella R. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067–72.PubMedCrossRefGoogle Scholar
  52. 52.
    Hunter SJ, Boyd A, O’Harte F, et al. Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in humans. Diabetes. 2003;52:492–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Savage C, St Clair EW. New therapeutics in rheumatoid arthritis. Rheum Dis Clin N Am. 2006;32:57–74.CrossRefGoogle Scholar
  54. 54.
    Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D: concepts and strategies. Clin Immunol. 2013;149:279–85.PubMedCrossRefGoogle Scholar
  55. 55.
    Noguchi M, Nakamura S, Russel S, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. 1993;262:1877–80.PubMedCrossRefGoogle Scholar
  56. 56.
    Wong HL, Pfeiffer R, Fears T, et al. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomark Prev. 2008;17:3450–6.CrossRefGoogle Scholar
  57. 57.
    Van Rompaey L, Galien R, van der Aar E, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191:3568–77.PubMedCrossRefGoogle Scholar
  58. 58.
    Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.PubMedCrossRefGoogle Scholar
  59. 59.
    Monti P, Brigatti C, Heninger AK, et al. Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4(+) and CD8(+) T-cells. Am J Transplant. 2009;9:2727–35.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Diabetes Research Institute (DRI)IRCCS San Raffaele Scientific InstituteMilanItaly
  2. 2.DFG-Center for Regenerative Therapies DresdenTechnische Universität DresdenDresdenGermany

Personalised recommendations